Companies interested in the award must work through their Technical Point of Contact (TPOC) and can contact the DoW Accelerated Research for Transition (ART) Program at [email protected]
Source: FDA briefing document, July 2026
1 775,00 3 600,00 2 980,00 600,00 214,00 540,00 360,00 1 650,00 1 305,00 650,00 545,00 500,00 700,00 700,00 770,00 5 270,00 4 790,00 338,04 1 188,00 550,00 395,00 6 600,00 5 040,00 4 050,00 2 950,00 1 304,64 2 300,00 650,00 1 300,00 990,00 1 200,00 1 900,00 910,00 750,00 910,00 750,00 3 900,00 3 900,00 3 900,00 4 500,00 5 900,00 12 300,00 12 300,00 12 300,00 12 300,00 12 300,00 12 300,00 12 300,00 12 300,00 12 300,00 14 200,00 14 200,00 18 500,00 25 000,00 2 700,00
This stack could theoretically: Suppress appetite more effectively than semaglutide Enhance calorie burn via glucagon activation Preserve lean mass while reducing fat mass Stabilize hunger hormones for long-term maintenance In early data and preclinical models, this combination produced unprecedented fat-loss percentages, suggesting a paradigm shift in obesity medicine
Peptide Form: Peptides in powder form are generally more stable than those in solution
